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Loss  of  muscle  mass  is  a  defining  feature  of   
cachexia of chronic disease. Patients suffering 
from cancer, chronic heart disease, chronic ob­
structive pulmonary disease, sepsis, and many 
other conditions experience involuntary weight 
loss and loss of muscle mass, which contributes 
significantly to mortality (Morley et al., 2006; 
Tisdale,  2009). A  decrease  in  volitional  food   
intake is often associated with cachexia but is 
not  solely  responsible  for  the  loss  of  muscle 
mass, as nutritional supplementation fails to 
substantially reverse changes in body weight   
(Evans et al., 1985). A common pathological 
feature of these disparate conditions is an in­
crease  in  circulating  inflammatory  cytokines. 
Systemic  administration  of  cytokines  results   
in muscle catabolism in experimental animals 
(Acharyya et al., 2004). Furthermore, genetic 
(Llovera et al., 1998) or pharmacologic block­
ade (Fujita et al., 1996) of cytokine signaling 
attenuates  experimental  cachexia.  Numerous 
studies  have  demonstrated  that  inflammatory 
cytokines can cause atrophic changes in cultured 
myotubes, and in vivo studies have demonstrated 
that activation of inflammatory signaling path­
ways are fundamental to the atrophy process 
(Strassmann  et  al.,  1992;  Zamir  et  al.,  1994; 
Acharyya et al., 2004; Doyle et al., 2011). How­
ever, the catabolic effects of inflammation in vivo 
have not been shown to depend exclusively on 
direct cytokine action on skeletal muscle.
Despite the well documented role of the 
brain  in  regulating  whole  body  metabolism, 
the  contribution  of  central  nervous  system 
(CNS) inflammation to muscle atrophy has not 
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Skeletal muscle catabolism is a co-morbidity of many chronic diseases and is the result of 
systemic inflammation. Although direct inflammatory cytokine action on muscle promotes 
atrophy, nonmuscle sites of action for inflammatory mediators are less well described. We 
demonstrate that central nervous system (CNS)–delimited interleukin 1 (IL-1) signaling 
alone can evoke a catabolic program in muscle, rapidly inducing atrophy. This effect is 
dependent on hypothalamic–pituitary–adrenal (HPA) axis activation, as CNS IL-1–induced 
atrophy is abrogated by adrenalectomy. Furthermore, we identified a glucocorticoid- 
responsive gene expression pattern conserved in models of acute and chronic inflammatory 
muscle atrophy. In contrast with studies suggesting that the direct action of inflammatory 
cytokines on muscle is sufficient to induce catabolism, adrenalectomy also blocks the 
atrophy program in response to systemic inflammation, demonstrating that glucocorticoids 
are requisite for this process. Additionally, circulating levels of glucocorticoids equivalent 
to those produced under inflammatory conditions are sufficient to cause profound muscle 
wasting. Together, these data suggest that a significant component of inflammation-
induced muscle catabolism occurs indirectly via a relay in the CNS.
© 2011 Braun et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months   
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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IL­1, food was removed from all cages at the time of injec­
tion. Central administration of IL­1 led to a significant and 
rapid induction of MAFbx, MuRF1, and Foxo1 mRNA in 
gastrocnemius (Gn) muscle 4–8 h after the injection (Fig. 2 a), 
demonstrating rapid activation of the catabolic program in 
skeletal muscle in response to central inflammation. Given the 
known role of PI3K/Akt signaling in the regulation of muscle 
mass, we examined Akt phosphorylation in muscle by West­
ern blot after acute i.c.v. IL­1 (Fig. 2 b). No changes were 
observed in the phosphorylation of Akt at any time point after 
i.c.v. IL­1 injection. To rule out the possibility that centrally 
administered IL­1 was leaking into the systemic circulation 
and having a direct impact on muscle, we examined p38 
MAPK phosphorylation in muscle. Signaling via this pathway 
occurs downstream of the type I IL­1 receptor (IL­1R1) and 
has been implicated in the regulation of MAFbx (Li et al., 
2005; Doyle et al., 2011). No changes were observed in p38 
phosphorylation at any time point after central IL­1 injec­
tion, suggesting that centrally injected cytokine is unlikely to 
be directly signaling in muscle (Fig. 2 b). We also examined 
circulating IL­1 levels after acute central IL­1 injection and 
found no changes at any time point examined (Table I).
We next examined whether the catabolic molecular 
mechanisms that are rapidly engaged after bolus i.c.v. IL­1 
injection can bring about muscle atrophy with time. Rats 
were infused with IL­1 into the lateral ventricle for 3 d via 
been examined. The CNS is a known target of cytokine signal­
ing in cachexia, where cytokines act on neural feeding circuits 
to mediate anorexia (Scarlett et al., 2007; Grossberg et al., 2010). 
Multiple inflammatory cytokines are induced in the hypothal­
ami of animals treated peripherally with LPS (Ogimoto et al., 
2006) or in tumor­bearing animals (Ropelle et al., 2007). When 
CNS IL­1 receptors are pharmacologically antagonized during 
systemic inflammation, anorexia and alterations in peripheral 
protein metabolism are ameliorated (Layé et al., 2000; Lloyd   
et al., 2003), suggesting that CNS inflammation plays a critical 
role in integrating the host response to disease.
In this paper, we present evidence that CNS inflamma­
tion is sufficient to induce muscle atrophy independent of 
substantial peripheral inflammation. Activation of the hypo­
thalamic–pituitary–adrenal (HPA) axis is both necessary and 
sufficient to explain the catabolic action of central inflamma­
tion. Consistent with the role of the brain as a central regu­
lator of metabolic homeostasis, this work implicates CNS 
cytokine signaling in regulating the muscle catabolism in re­
sponse to systemic inflammation.
RESULTS
CNS inflammation and muscle catabolism are coincident states
CNS inflammation and muscle catabolism are common features 
in experimental models of cachexia. Mice treated with LPS or 
implanted with the Lewis lung carcinoma (LLC) robustly in­
crease the expression of inflammatory cytokines in the hypo­
thalamus (Fig. 1, a and c). LPS administration results in 
generalized inflammation, as indicated by the up­regulation of 
both IL­1 and TNF. In contrast, tumor growth resulted only 
in the up­regulation of IL­1. Furthermore, after systemic LPS 
administration, IL­1 expression is strongly induced within the 
hypothalamic arcuate nucleus as shown by in situ hybridiza­
tion, demonstrating endogenous production within the CNS   
(Fig. 1 b). Muscle loss in cachexia occurs as a result of a decrease 
in protein synthesis and a concomitant increase in protein degra­
dation (Baracos et al., 1995) that occurs principally via the ubiq­
uitin proteasome system (Mitch et al., 1994; Baracos et al., 1995; 
Price et al., 1996). Muscle­specific E3 ubiquitin ligases, muscle 
atrophy F­box (MAFbx or atrogin­1), and muscle ring finger 
protein 1 (MuRF1; Bodine et al., 2001a; Gomes et al., 2001) are 
induced in catabolic muscle and are regulated by the forkhead 
box (Foxo) family of transcription factors (Sandri et al., 2004). 
Increased expression of MAFbx and MuRF1 occurs in all forms 
of atrophy studied (Lecker et al., 2004). Simultaneous with cen­
tral inflammation, the atrophy program is activated in skeletal 
muscle, marked by the up­regulation of MAFbx, MuRF1, and 
Foxo1 (Fig. 1, a and c), which in the case of tumor­bearing ani­
mals occurs in the context of muscle mass loss (Fig. 1 d).
Acute and chronic central administration of IL-1 results  
in muscle atrophy
To determine whether inflammatory signaling in the CNS 
plays a role in directing muscle catabolism, mice were admin­
istered 10 ng IL­1 or vehicle (Veh) by intracerebroventricu­
lar (i.c.v.) injection. To control for the anorectic effects of 
Figure 1.  CNS inflammation and muscle catabolism occur simulta-
neously. (a) Atrophy gene expression in mouse Gn and cytokine expression 
in mouse hypothalamic blocks (Hypo) 8 h after i.p. LPS (250 µg/kg) or Veh 
was measured by real-time PCR (n = 5–7/group for Gn and 5/group for 
Hypo). Values are relative to GAPDH for Gn and 18s RNA for Hypo. (b) In situ 
hybridization for IL-1 mRNA in the arcuate nucleus of the hypothala-
mus (2.80 relative to bregma; 3V, third ventricle) 8 h after LPS adminis-
tration. Veh-treated animals showed no specific signal at this exposure 
time. (c) Atrophy gene expression in Gn and cytokine expression in hypo-
thalamic blocks in mice bearing LLC tumors (or sham) were measured by 
real-time PCR (n = 5–9/group). Values are relative to GAPDH for Gn and 18s 
RNA for Hypo. (d) Gn muscle weight normalized to initial body weight (BW) 
and muscle weight change relative to Veh in LLC tumor bearing animals  
(n = 5–9/group). Bar, 100 µm. Data are represented as mean ± SEM.  
*, P < 0.05; ***, P < 0.001 as calculated by unpaired Student’s t test.JEM Vol. 208, No. 12 
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sustained decrease in food intake over the course of the 3­d 
study. Although Veh­treated animals consumed 78.6 ± 2.2 g 
of food over the 3­d period, IL­1–treated animals only con­
sumed 45.29 ± 4.0 g. Similar to acute injection, chronic i.c.v. 
infusion  of  IL­1  increased  the  expression  of  MAFbx, 
MuRF1, and Foxo1 mRNAs in muscle (Fig. 2 c). The most 
pronounced differences were seen in the Gn and extensor 
digitorum longus (EDL), which are predominantly composed 
osmotic minipumps at a dose (10 ng/h) thought to mimic 
endogenous pathophysiologic concentrations under inflam­
matory conditions (Plata­Salamán et al., 1996). This dose is 
also far below those given peripherally to induce muscle ca­
tabolism or anorexia (Bodine et al., 2001a; Whitaker and 
Reyes, 2008). To control for the effects of IL­1 on food   
intake, a subset of Veh­treated animals was pair fed (PF) to the 
IL­1–treated animals. Central IL­1 treatment led to a 
Figure 2.  IL-1 signaling in the CNS produces muscle catabolism. (a) Atrophy gene expression in mouse Gn muscle (Gn) after acute i.c.v. IL-1 
injection (10 ng, n = 6–9/group) or Veh. (b) Akt and p38 phosphorylation in Gn after acute i.c.v. IL-1 was measured by Western blotting (n = 6–9/group). 
(c–g) Rats were i.c.v. infused for 3 d with IL-1 (10 ng/h) or Veh (n = 8–11/group). A subset of Veh-treated animals were PF to IL-1–treated animals.  
(c) Atrophy gene expression in rat muscle (Gn, Soleus, and EDL) after 3-d i.c.v. IL-1 or Veh infusion was measured by real-time PCR. Reported values are 
relative to GAPDH. (d) Body composition after 3-d IL-1 infusion. (e) Muscle weight normalized to initial body weight (BW) and weight change relative to 
Veh. (f) Mean fiber CSA in WGn and soleus and frequency distribution in Gn. (g) WGn immunostained for laminin (red), delineating fiber area, and Myosin 
IIb (green). Bars, 100 µm. Data are represented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 calculated by one-way (c–f) or two-way (a and b) 
ANOVA with Bonferroni’s corrected t test.
Table I.  Circulating cytokines, growth factors, and hormones in acute IL-1–treated mice
Treatment IL-6 IL-1 IGF-1 Corticosterone
pg/ml pg/ml ng/ml ng/ml
2-h Veh 13 ± 3 22 ± 6 225 ± 11 104 ± 16
2-h 10-ng IL-1 298 ± 35*** 25 ± 6 216 ± 18 397 ± 30***
4-h Veh 21 ± 6 16 ± 3 200 ± 8 103 ± 14
4-h 10-ng IL-1 69 ± 14 28 ± 6 168 ± 9 258 ± 35***
8-h Veh 13 ± 6 46 ± 15 173 ± 4 115 ± 34
8-h 10-ng IL-1 8 ± 2 32 ± 5 205 ± 6 72 ± 10
WT mice received i.c.v. injections of IL-1. Animals were sacrificed at 2, 4, and 8 h after the injection (n = 6-9/group). Plasma IL-6, IL-1, and IGF-1 levels were measured by 
ELISA and corticosterone was measured by RIA. ***, P < 0.001 versus corresponding Veh-injected control as calculated by two-way ANOVA with Bonferroni’s post test.2452 Inflammation induces atrophy via the CNS | Braun et al.
in the CNS is sufficient to induce muscle atrophy, predomi­
nantly in fast twitch fibers. Furthermore, IL­1 is a far more 
potent catabolic mediator when administered centrally than 
when given peripherally.
Central melanocortin signaling is not necessary  
for IL-1–induced muscle atrophy
Pharmacologic blockade of the type 4 melanocortin receptor 
(MC4R) prevents IL­1–induced anorexia (Whitaker and 
Reyes, 2008) and attenuates lean mass loss in experimental 
cachexia (Marks et al., 2001; Wisse et al., 2001; Cheung   
et al., 2005). Furthermore, the MC4R is critical to the CNS 
regulation of many other facets of metabolism (Nogueiras 
et al., 2007; Perez­Tilve et al., 2010). Finally, inflammatory 
challenges specifically up­regulate IL­1 mRNA in the arcu­
ate nucleus, which contains the proximal neurons of the cen­
tral melanocortin system. Based on this, we sought to examine 
whether the acute food intake–independent changes in mus­
cle catabolism initiated by IL­1 are dependent on signaling 
at  the  MC4R.  WT  mice  and  mice  lacking  a  functional 
MC4R (MC4RKO) were injected i.c.v. with 10 ng IL­1 
and were sacrificed 8 h after injection. Surprisingly, IL­1 
led to a similar increase in the mRNA for MAFbx, MuRF1, 
and Foxo1 in the Gn of both WT and MC4RKO mice 
(Fig. 4 a). To further examine the role of the central melano­
cortin system in regulating muscle catabolism independent 
from its effects on food intake, rats were injected i.c.v. with 
1 nmol melanotan II (MTII), an agonist at the type 3 and 4 
melanocortin receptors, and were sacrificed 6 h after injec­
tion. MTII failed to increase the mRNA for MAFbx, MuRF1, 
or Foxo1 in the Gn (Fig. 4 b). To determine the impact of 
increased signaling via the MC4R in the chronic state, 1 nmol 
MTII was administered i.c.v. every 12 h for 36 h (four injec­
tions), and animals were sacrificed 2 h after the final injec­
tion.  To  control  for  the  decreased  food  intake 
associated with MTII treatment, Veh­injected con­
trol animals were PF with MTII­treated animals. 
Chronic MTII failed to increase the mRNA for 
MAFbx or Foxo1 relative to PF controls but led to a 
small increase in MuRF1 mRNA in the Gn (Fig. 4 c). 
No changes in the expression of MAFbx, MuRF1, 
or Foxo1 were seen in the soleus (Fig. 4 c). Both 
MTII­treated and PF animals lost weight over the 
course of the experiment, but there was no differ­
ence between groups (Fig. 4 d). MTII treatment 
of fast twitch fibers. These effects were largely independent 
from food intake as PF animals failed to show similar changes 
in gene expression. In contrast, the induction of MAFbx, 
MuRF1, and Foxo1 in the soleus was relatively small. Central 
IL­1 infusion also resulted in significant alterations in body 
composition, resulting in significant food intake–independent 
losses of both body weight and lean mass (Fig. 2 d). Although 
significant fat mass loss occurred with IL­1 treatment, these 
changes were paralleled by the PF group. Concurrent with 
the changes in body composition, significant food intake–
independent loss of Gn and EDL muscles were observed 
(Fig. 2 e). To examine whether the loss of muscle mass seen 
with i.c.v. IL­1 treatment is the result of myofibrillar atro­
phy, fiber cross­sectional area (CSA) was measured in regions 
of the Gn and soleus muscle composed of fast (white Gn 
[WGn]) and slow (soleus) fibers. WGn fiber CSA was signifi­
cantly reduced by IL­1 treatment but unaltered in PF ani­
mals (Fig. 2, f and g). In contrast, soleus fiber CSA was only 
mildly reduced (Fig. 2 f).
To confirm that centrally infused IL­1 is not diffusing 
systemically and acting directly on muscle, we infused IL­1 
i.p. at the same dose given i.c.v (10 ng/h) for 3 d. This pe­
ripheral IL­1 treatment did not induce MAFbx, MuRF1, or 
Foxo1 mRNA in the Gn, soleus, or EDL (Fig. 3 a). Unlike 
i.c.v. infusion, i.p. IL­1 delivered at this dose did not affect 
Gn, soleus, and EDL weights (Fig. 3 b). In addition, periph­
eral IL­1 infusion did not significantly alter body weight, 
lean mass, or fat mass (Fig. 3 c) and failed to alter fiber CSA 
in the WGn or soleus (Fig. 3, d and e). To determine whether 
low dose systemic IL­1 infusion was causing increases in 
circulating IL­1 levels, we measured IL­1 in the plasma of 
these animals. Circulating IL­1 levels were below the limit 
of detection (LOD) in all samples (LOD = 93.6 pg/ml; not de­
picted). Collectively, these data demonstrate that inflammation 
Figure 3.  Peripheral infusion of low dose IL-1 does not 
cause atrophy. Rats were i.p. infused (10 ng/h, n = 7–8/group) 
for 3 d with IL-1 or Veh solution. (a) Atrophy gene expression in 
rat muscle (Gn, Soleus, and EDL) after 3-d i.p. IL-1 infusion 
was measured by real-time PCR. Reported values are relative 
to GAPDH. (b) Muscle weight normalized to initial body weight 
(BW). (c) Body composition after 3-d IL-1 infusion. (d) Mean 
fiber CSA in WGn and soleus and frequency distribution in Gn. 
(e) WGn immunostained for laminin (green) delineating fiber 
area. Bars, 100 µm. Data are represented as mean ± SEM.JEM Vol. 208, No. 12 
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(denoted in red). The complete dataset has been deposited 
in the GEO Omnibus database (GEO Series accession no. 
GSE26766). Significantly regulated genes were grouped 
based on their known functions in skeletal muscle. At the 
2­ and 4­h time points there was a pronounced regulation 
of  genes  involved  in  regulating  the  inflammatory/anti­ 
inflammatory balance. At the 4­ and 8­h time points, altera­
tions  in  nutrient  signaling  were  evident,  with  changes  in 
mammalian target of rapamycin (mTOR) and AMP­activated 
protein kinase pathway members. An oxidative stress re­
sponse was also observed at later time points. Genes involved 
in cell cycle regulation and myogenic differentiation were 
also did not lead to significant food intake–independent losses 
of fat mass, lean mass, Gn, or soleus weight (Fig. 4, d and e). 
These results argue that the CNS mechanism by which IL­1 
induces food intake–independent muscle catabolism is not 
dependent on signaling at the MC4R.
Central IL-1 injection induces a transcriptional program  
in skeletal muscle, which is analogous to that seen in other 
forms of atrophy
Changes in the mRNA profile of skeletal muscle undergoing 
atrophy have been extensively characterized, revealing a con­
served pattern of gene expression (Lecker et al., 2004). To 
gain insight into how central IL­1 induces muscle catabo­
lism,  we  performed  cDNA  microarray  analysis  of  mouse 
skeletal muscle RNA at 2, 4, and 8 h after i.c.v. IL­1 injec­
tion.  Statistical  analysis  with  a  false  discovery  rate  of  1% 
yielded 494 significantly regulated genes. This list was further 
narrowed to 100 genes by restricting it to genes that were at 
least 1.75 fold up­ or down­regulated at any of the three time 
points (Fig. 5, Fig. S1, and Table S2). The expression pattern 
of 10% of these genes was confirmed by real­time PCR 
Figure 4.  Signaling through the MC4R is not a major contributor 
to the muscle catabolism independent of food intake. (a and b) Atro-
phy gene expression in WT and MC4RKO mouse Gn 8 h after acute i.c.v.  
IL-1 injection (10 ng, n = 8–9/group; a) and in rat Gn 6 h after acute i.c.v. 
MTII (1 nmol, n = 6–9/group; b) or Veh injection was measured by real-
time PCR. (c–e) Rats were treated for 36 h (chronic) with MTII or Veh  
(1 nmol/12 h × 4, n = 7–8/group). Veh-treated animals were PF to the MTII 
treatment group. (c) Gene expression in rat Gn and soleus after chronic 
MTII treatment was measured by real-time PCR. Reported values are rela-
tive to GAPDH. (d) Body composition after chronic MTII treatment.  
(e) Muscle weight normalized to initial body weight (BW). The dotted line  
in a represents Veh-treated controls at a relative quantity of 1. Data are rep-
resented as mean ± SEM. **, P < 0.01, as calculated by an unpaired Stu-
dent’s t test. (a) Analyzed by two-way ANOVA with Bonferroni’s corrected  
t test with no significant effect of genotype found. (b, d, and e) Analyzed 
by unpaired Student’s t test, with no comparisons reaching P < 0.05.
Figure 5.  Central IL-1 treatment induces rapid and dynamic 
changes in skeletal muscle gene expression. WT mice received lateral 
ventricle injections of IL-1 (I) or Veh (V). Food was removed from the 
cages at the time of injection, and animals were sacrificed at 2, 4, and 8 h 
after the injection (n = 3–5/group). Skeletal muscle RNA was hybridized to 
Affymetrix Exon 1.0 ST arrays. Data were analyzed for a false discovery rate 
of 0.01. Genes that were >1.75-fold up- or down-regulated at any time 
point were categorized based on their annotated and published functions. 
Heat map values are log2 normalized array intensities. Genes with differen-
tial expression confirmed by real-time PCR are indicated in red (Fig. S1).  
§ indicates genes that are annotated as glucocorticoid responsive or are 
regulated in muscle by glucocorticoids in published array datasets.2454 Inflammation induces atrophy via the CNS | Braun et al.
HPA axis. Given the significant glucocorticoid­regulated gene 
expression signature seen in response to central inflammation, 
we measured serum corticosterone (the predominant circulat­
ing glucocorticoid in rodents) by radioimmunoassay. Similar 
to IL­6, serum corticosterone levels were highest at 2 h after 
acute i.c.v. IL­1, reaching 397 ± 30 versus 104 ± 16 ng/ml 
in Veh­treated animals, and had returned to baseline by 8 h 
after injection (Table I). In contrast with plasma IL­6 levels, 
chronic i.c.v. infusion of IL­1 led to a sustained increase in 
circulating corticosterone at the time of sacrifice relative to 
Veh­treated animals, (183 ± 40 ng/ml for IL­1–infused 
animals vs. 37 ± 21 ng/ml for Veh­treated animals; Table II).
Activation of the HPA axis is necessary for the muscle 
catabolic effects of i.c.v. IL-1
To explore the involvement of HPA axis activation in i.c.v. 
IL­1–induced muscle catabolism, mice received acute i.c.v. 
injections of 10 ng IL­1 and were treated with the gluco­
corticoid/progesterone antagonist mifepristone. Mifepristone 
treatment attenuated the induction of MAFbx, MuRF1, and 
Foxo1 mRNA by i.c.v. IL­1 (Fig. 6 a and Table S1). To 
confirm these findings, we used adrenalectomized (ADX) 
mice  with  low  physiological  corticosterone  replacement. 
This allowed us to examine whether tonic glucocorticoids 
are a permissive factor in muscle catabolism or whether an 
increase in circulating corticosterone is the driver of atrophy. 
In ADX animals, i.c.v. IL­1 failed to induce MAFbx to the 
same degree as seen in sham­operated animals, and the in­
duction of MuRF1 and Foxo1 by i.c.v. IL­1 injection was 
completely blocked (Fig. 6 b and Table S1). In addition, the 
induction of the catabolic transcription factor Krüpple­like 
factor 15 (KLF15), which transactivates MAFbx and MuRF1 
(Shimizu et al., 2011), was blocked by ADX. These data 
demonstrate that an increase in circulating glucocorticoids is 
necessary for the acute activation of the atrophy program in 
response to i.c.v. IL­1.
To determine if intact adrenals are necessary for food 
intake­independent myofibrillar atrophy, we infused IL­1 or 
Veh i.c.v. for 3 d in ADX corticosterone­replaced rats. To 
control for the effects of food intake, Veh­treated animals 
were PF to IL­1–treated animals. No significant differences 
were  observed  in  the  expression  of  MAFbx,  MuRF1,  or 
Foxo1 in the Gn, soleus, or EDL (Fig. 6 c). There were statis­
tically nonsignificant trends toward an increase in the levels 
significantly affected, suggesting alterations in muscle regen­
eration. Comparison of this dataset with two separate gene 
expression array studies evaluating muscle gene expression in 
response to glucocorticoid administration revealed multiple 
glucocorticoid­responsive  genes  (Fig.  5,  marked  by  §;   
Almon et al., 2007; Wu et al., 2010). These data implicate 
HPA axis activation in mediating the changes in gene expres­
sion in skeletal muscle after central IL­1 treatment.
Regulation of circulating growth factors and cytokines  
after i.c.v. IL-1
Plasma levels of IL­6 were examined by ELISA after acute   
i.c.v. IL­1 injection, as circulating IL­6 increases after central 
IL­1 administration (De Simoni et al., 1990), and IL­6 has 
been implicated in mediating muscle catabolism (Fujita et al., 
1996). A small induction of circulating IL­6 was observed at 
early time points, with a peak of 298 ± 35 pg/ml at 2 h versus 
13 ± 3 pg/ml in Veh­treated animals, with levels returning to 
baseline by 8 h (Table I). Despite a marked increase, these levels 
of IL­6 are quite low in comparison with those found in ani­
mals undergoing systemic inflammatory challenge, where peak 
serum values approach 7,000 pg/ml (Hansen et al., 2000). To 
examine whether significant IL­6 production or signaling was 
occurring in muscle after central IL­1 treatment, we mea­
sured the expression of IL­6 and its downstream feedback in­
hibitor suppressor of cytokine signaling 3 (SOCS3). We found 
no changes in either IL­6 or SOCS3 gene expression in muscle 
at any time point after central injection of IL­1, suggesting 
that significant IL­6 signaling does not occur in muscle after 
i.c.v. IL­1 injection (unpublished data). Additionally, sus­
tained delivery of IL­1 into the CNS did not lead to an in­
crease in circulating IL­6 levels at the end of 3 d of i.c.v. 
infusion (Table II), suggesting that the elevation of IL­6 after 
acute central IL­1 treatment is a transient phenomenon.
Circulating insulin­like growth factor 1 (IGF­1) contributes 
to the regulation of the anabolic/catabolic balance in skeletal 
muscle (Stitt et al., 2004). No differences in IGF­1 were observed 
between Veh and IL­1–treated animals at any time point, with 
all values falling in the expected normal range (Table I). IGF­1 
levels were also measured in animals infused i.c.v. with IL­1 
for 3 d. Serum IGF­1 levels were unaffected by chronic IL­1 
administration relative to ad lib–fed controls (Table II).
Glucocorticoids are known mediators of muscle catabo­
lism (Bodine et al., 2001a), and inflammation activates the 
Table II.  Circulating cytokines, growth factors, and hormones in 3-d IL-1–treated rats
Treatment IL-6  IGF-1 Corticosterone
pg/ml ng/ml ng/ml
Ad lib 106 ± 44 1,075 ± 63 48 ± 29
PF Undetectable (LOD = 62.5) 851 ± 41* 70 ± 27
IL-1 102 ± 26 1013 ± 46 183 ± 40*
Rats were infused for 3 d with IL-1 into the lateral ventricle using an osmotic minipump. Control animals were infused over the same time period with a Veh solution and 
were fed ad lib or PF with IL-1–treated animals (n = 8–11/group). Plasma IL-6 and IGF-1 were measured by ELISA, and corticosterone was measured by RIA. Data are 
represented as mean ± SEM. *, P < 0.05 versus ad lib control as calculated by one-way ANOVA and Bonferroni’s post test or Kruskal-Wallis test and Dunn’s multiple 
comparison post test where appropriate.JEM Vol. 208, No. 12 
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were observed in the weights of Gn, soleus, or EDL muscles 
(Fig. 6 e). Muscle fiber CSA was also not significantly de­
creased by IL­1 infusion relative to PF controls in either the 
WGn or soleus (Fig. 6, f and g). Centrally infused IL­1 was 
not leaking systemically, as the majority (19/20) of animals 
had plasma IL­1 levels below the LOD (LOD = 93.6 pg/ml; 
not depicted).
Central IL-1 induces a glucocorticoid-dependent 
transcriptional program that is common to models of acute 
and chronic systemic inflammation
To study the extent to which the transcriptional program ini­
tiated by central IL­1 is dependent on glucocorticoid signal­
ing, we selected several genes identified by the array analysis 
to examine in ADX mice. The adipokine lipocalin­2 (Lcn2) 
and the steroid hormone responsive transcript decidual pro­
tein regulated by progesterone (Depp) were highly induced by 
central IL­1 administration, a response only slightly attenu­
ated by adrenalectomy (Fig. 7 a and Table S1). In contrast, the 
induction of the oxidative stress response genes metallothio­
nein­2  (Mt2)  and  uncoupling  protein­3  (Ucp3)  was  com­
pletely blocked by ADX. The up­regulation of mTOR 
of MAFbx and MuRF1 mRNA in the Gn (MAFbx mRNA, 
P = 0.09; MuRF1 mRNA, P = 0.12) and EDL (MAFbx 
mRNA, P = 0.19; MuRF1 mRNA, P = 0.34). Central IL­1 
infusion  failed  to  generate  a  significant  decrease  in  body 
weight, fat mass, or lean mass beyond that seen in PF animals 
(Fig. 6 d), although a statistically nonsignificant trend was 
seen toward the loss of lean mass (P = 0.13). No differences 
Figure 6.  HPA axis activation is necessary for i.c.v. IL-1–induced 
muscle catabolism. (a and b) Muscle atrophy gene expression in mife-
pristone (Mife) or Veh-treated (n = 6–8/group; a) and ADX or sham (n = 
7–8/group; b) mouse Gn 8 h after acute i.c.v. 10-ng IL-1 injection was 
measured by real-time PCR. (c–g) ADX rats were treated for 3 d with 
chronic i.c.v. IL-1 or Veh (10 ng/h, n = 8–9/group). Veh-treated animals 
were PF to the IL-1–treated group. (c) Atrophy gene expression in ADX 
rat muscle after 3-d chronic i.c.v. IL-1 infusion was measured by real-
time PCR. Reported values are relative to GAPDH. (d) Body composition. 
(e) Muscle weight normalized to initial body weight (BW). (f) Mean fiber 
CSA in WGn and soleus and frequency distribution in WGn. (g) WGn  
immunostained for laminin (green) delineating fiber area. The dotted lines 
in a and b represent Veh-treated controls at a relative quantity of 1. Bars, 
100 µm. Data are represented as mean ± SEM. *, P < 0.05; **, P < 0.01;  
***, P < 0.001 by two-way ANOVA with Bonferroni’s corrected t test (a and b; 
raw data in Table S1) or by unpaired Student’s t test (d–g), with no com-
parisons reaching P < 0.05.
Figure 7.  Glucocorticoid-driven gene expression signatures are 
present in skeletal muscle during central and peripheral inflamma-
tion. (a) Gene expression in ADX mouse Gn muscle 8 h after acute i.c.v. 
10-ng IL-1 injection or Veh was measured by real-time PCR (n = 6–8/
group). (b) Muscle gene expression in mouse Gn 8 h after i.p. LPS (250 µg/kg) 
or Veh was measured by real-time PCR (n = 5–7/group). (c) Gene ex-
pression in Gn in mice bearing LLC tumors (or sham) was measured by 
real-time PCR (n = 5–9/group). Reported values are relative to GAPDH. 
Data represented as mean ± SEM. The dotted line in a represents Veh-
treated controls at a relative quantity of 1. *, P < 0.05; **, P < 0.01;  
***, P < 0.001 by unpaired Student’s t test (b and c) or two-way ANOVA 
with Bonferroni’s corrected t test (a; raw data in Table S1).2456 Inflammation induces atrophy via the CNS | Braun et al.
Despite the low­grade peripheral in­
flammation in tumor­bearing animals, 
many of the genes examined (five of 
nine) were regulated in skeletal mus­
cle. Importantly, the glucocorticoid 
dependent mTOR regulators Sesn1 
and  REDD1  were  up­regulated  in 
the muscle of tumor­bearing animals, 
demonstrating that glucocorticoid 
signaling  may  contribute  to  the 
pathogenesis of cancer cachexia.
HPA axis activation is necessary and sufficient for muscle 
wasting driven by central and peripheral inflammation
To examine the role of HPA axis activation in peripheral 
inflammation­induced  activation  of  the  atrophy  program, 
250 µg/kg LPS was administered to ADX mice. The LPS­
mediated induction of MAFbx was attenuated in ADX mice, 
and the induction of MuRF1 and Foxo1 were completely 
prevented  in  ADX  animals  (Fig.  8  a).  The  induction  of 
KLF15, REDD1, and Sestrin-1 by LPS was also completely 
blocked in ADX mice. Collectively, this demonstrates that 
peripheral inflammation­mediated activation of the atrophy 
program requires intact adrenal glands.
Although high­dose administration of synthetic gluco­
corticoids induces substantial atrophy, it remains unknown 
whether the lower levels of circulating corticosterone evoked 
by inflammation are sufficient to induce atrophy. To examine 
this possibility, rats were implanted with sustained release cort 
pellets at a dose known to produce circulating concentrations 
approximating levels seen in inflamed animals (Hansen et al., 
2000; Kovács et al., 2000). Rats were implanted with 100 or 
2 × 100 mg (200 mg) corticosterone tablets, achieving mean 
circulating levels of 321.8 ± 43.0 and 908.5 ± 223.7 ng/ml, 
pathway members Sestrin-1 (Sesn1) and regulated in develop­
ment and DNA damage responses (REDD1 or Ddit4), as well 
as the downstream target Foxo3, was also inhibited by ADX. 
The anti­myogenic basic helix­loop­helix transcription factor 
inhibitor of DNA binding 3 (Id3) was also induced by central 
IL­1 treatment in a glucocorticoid­dependent manner. The 
cytoskeletal protein kyphoscoliosis peptidase (KY) is dramati­
cally down­regulated by central inflammation an effect par­
tially blocked by ADX. We also examined myostatin gene 
expression in skeletal muscle, given its known critical role in 
the regulation of muscle mass (Zhou et al., 2010; Zhang et al., 
2011). Myostatin was modestly induced by central IL­1 ad­
ministration and this induction was completely blocked by 
adrenalectomy (Fig. 6 a). Collectively, these genes show a 
pattern of regulation that is largely dependent on an intact 
HPA axis, although some features are independently regu­
lated. To confirm this expression pattern in a model of 
systemic inflammation, we examined the expression of these 
genes in LPS and tumor­associated muscle catabolism (Fig. 7, 
b and c). An identical pattern of regulation was observed in 
LPS­treated animals, suggesting a significant glucocorticoid 
effect on skeletal muscle in response to peripheral inflammation. 
Figure 8.  Glucocorticoid signaling con-
tributes to atrophy as a result of sys-
temic inflammation. (a) Gene expression in 
ADX mouse Gn muscle 8 h after i.p. LPS  
(250 µg/kg) or Veh was measured by real-time 
PCR (n = 6–8/group). (b–f) Rats were treated 
for 3 d with corticosterone (100 or 200 mg; 
n = 6–7/group). (b) Gene expression in rat 
muscle (Gn, soleus, and EDL). Reported val-
ues are relative to GAPDH. (c) Muscle weight 
normalized to initial body weight (BW) and 
weight change relative to Veh. (d) Body 
composition after 3-d corticosterone treat-
ment. (e) Mean fiber CSA in WGn and soleus 
and frequency distribution in Gn. (f) WGn 
immunostained for laminin (green) delineat-
ing fiber area. The dotted line in a represents 
Veh-treated controls at a relative quantity of 
1. Bars, 100 µm. Data represented as mean ± 
SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 
calculated by one-way (b–f) or two-way (a) 
ANOVA with Bonferroni’s corrected t test 
(raw data in Table S1).JEM Vol. 208, No. 12 
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central IL­1 signaling attenuates many of the behavioral (Layé 
et al., 2000) and metabolic (Gourine et al., 1998; Lloyd et al., 
2003) features of inflammatory disease. Our data show that 
central  inflammation  initiates  significant  muscle  atrophy. 
Although we have demonstrated that central Il­1 is sufficient 
for this effect, it is unlikely to be the only mediator during 
systemic inflammation, as many cytokines activate the HPA 
axis (Akita et al., 1995; Bethin et al., 2000). We demonstrate 
specific production of IL­1 within the arcuate nucleus under 
inflammatory conditions. The arcuate also contains two neu­
ronal groups that are known to express the IL­1R1: POMC 
(Scarlett et al., 2007) and AgRP (Scarlett et al., 2008) neurons. 
The net effect of IL­1 on these two neuronal groups is to 
increase signaling at the MC4R, decreasing food intake. In 
accordance with this, the anorexia associated with IL­1 ad­
ministration  is  completely  prevented  by  blockade  of  the 
MC4R (Whitaker and Reyes, 2008). Furthermore, the loss of 
lean mass associated with cancer cachexia and LPS administra­
tion is prevented by blockade of the MC4R (Marks et al., 
2001; Wisse et al., 2001). Surprisingly, we found that signal­
ing at the MC4R is not necessary for central IL­1–induced 
muscle catabolism, and MC4R activation is not sufficient to 
produce significant muscle catabolism. These results are in 
disagreement with previous work showing a protective effect 
of melanocortin blockade on body weight and lean mass in 
experimental cachexia. However, these prior studies did not 
separate the powerful effects of melanocortin blockade on 
food intake from its effects on body composition. Given the 
minor regulation of MuRF1 by the central melanocortin sys­
tem, and the effects of the melanocortin system on food in­
take, it is possible that the protective effects of melanocortin 
blockade in experimental cachexia are the result of the com­
bination of these two factors alone.
The precise neuroanatomic substrate via which IL­1 
exerts its catabolic effect remains unknown. However, given 
that the major downstream mediator of central inflammation­
induced muscle catabolism is activation of the HPA axis, 
there is significant evidence to implicate endothelial IL­1R1 
as a crucial mediator of this effect. Activation of corticotropin­
releasing hormone neurons in the paraventricular nucleus 
(the hypothalamic component of the HPA axis) by central 
or peripheral IL­1 is blocked by knockdown of endothe­
lial IL­1R1 (Ching et al., 2007). Furthermore, a compo­
nent  of  this  effect  is  mediated  via  endothelium­derived 
prostaglandin signaling in medullary catecholaminergic neurons 
projecting to paraventricular neurons, activating the HPA 
axis (Ericsson et al., 1997; Serrats et al., 2010). Future loss­
of­function studies will likely examine the role of inflamma­
tory signaling at the level of the cerebrovascular endothelium 
in mediating muscle catabolism. In addition, there is a great 
deal of evidence that pituitary corticotrophs can be di­
rectly activated by inflammatory cytokines. Both leukemia 
inhibitory factor and IL­6 can directly activate pituitary 
corticotrophs, leading to the release of ACTH indepen­
dent of hypothalamic signaling (Akita et al., 1995; Bethin   
et al., 2000).
respectively, versus undetectable levels (LOD = 25 ng/ml) in 
sham animals. Both treatments significantly induced MAfbx, 
MuRF1, and Foxo1 to largely the same degree (Fig. 8 b). We 
additionally assessed the expression of the mTOR regulators 
REDD1, Sestrin-1, and KLF15, as well as the glucocorticoid 
responsive antiinflammatory mediator IB (Scheinman et al., 
1995), in Gn after corticosterone treatment. All four genes 
were significantly elevated by 100 and 200 mg corticosterone 
treatment (Fig. 8 b). Significant weight loss was observed in 
the Gn and EDL muscle with relative sparing of the soleus 
(Fig. 8 c). Both 100­ and 200­mg treatments also resulted in 
a significant loss of body weight, fat mass, and lean mass 
(Fig. 8 d). Significant myofibrillar atrophy was evident in the 
WGn from both corticosterone treatment groups but was 
largely absent in the soleus (Fig. 8, e and f). In nearly all cases, 
little difference was seen between 100­ and 200­mg treat­
ments, demonstrating that the atrophy program is maximally 
activated  by  corticosterone  levels  within  the  physiological 
range evoked by inflammation.
DISCUSSION
The CNS serves as a central regulator of whole body energy 
balance coordinating metabolic homeostasis in multiple pe­
ripheral  tissues  (Minokoshi  et  al.,  2002;  Nogueiras  et  al., 
2007; Shiuchi et al., 2009). Under normal physiological con­
ditions, anabolism and catabolism are regulated such that en­
ergy needs are met. During acute infection, skeletal muscle is 
mobilized to provide substrates to fuel the necessary increases 
in immune function. However, in cases of chronic disease 
where inflammation persists, muscle protein is excessively 
mobilized, leading to profound muscle atrophy. The regula­
tion of protein mobilization by inflammation occurs at nu­
merous levels. The direct action of inflammatory signaling 
molecules on skeletal muscle has been extensively examined, 
as has the contribution of IGF­1 signaling (Bodine et al., 
2001b; Rommel et al., 2001; Acharyya et al., 2004; Stitt   
et al., 2004; Li et al., 2005, 2009; Doyle et al., 2011). The 
data we present in this paper demonstrate that CNS integra­
tion of inflammatory signaling also plays a critical role in reg­
ulating the anabolic/catabolic balance in muscle via activation 
of the HPA axis. Given that a multitude of inflammatory dis­
eases with underlying muscle catabolism are also marked by 
CNS inflammation, a central mechanism must now be con­
sidered when describing muscle atrophy.
To model endogenous production of IL­1 in the CNS 
and its impact on skeletal muscle, we used i.c.v. injection to 
deliver physiologically relevant doses of this prototypical in­
flammatory cytokine. Central injection of IL­1 is believed to 
mimic its production by the choroid plexus and circumven­
tricular organs (Konsman et al., 2000) and is therefore a model 
of endogenous inflammation. Hypothalamic IL­1 produc­
tion is a conserved feature of a multitude of conditions associ­
ated with muscle catabolism, including cancer cachexia (Fig. 1; 
Plata­Salamán et al., 1998; Ropelle et al., 2007), peripheral 
cytokine administration (Gayle et al., 1997), and endotoxemia 
(Fig. 1; Ogimoto et al., 2006). Additionally, antagonism of 2458 Inflammation induces atrophy via the CNS | Braun et al.
likely subtherapeutic in these studies. Given the glucocorti­
coid responsive gene expression signature seen in the skeletal 
muscle of tumor­bearing animals and the limitations of the 
aforementioned studies, the involvement of glucocorticoids in 
tumor­associated muscle wasting appears likely. Future ge­
netic loss­of­function studies will likely shed light on the con­
tribution of glucocorticoids to muscle wasting in cancer.
The molecular mechanisms underlying glucocorticoid­
induced atrophy have been extensively studied at the level of 
skeletal muscle and are driven to a large degree by transcrip­
tional changes. Our array analysis is unique in the literature 
in that it offers insight into these early transcriptional events 
that take place after endogenous activation of the HPA axis. 
The up­regulation of catabolic machinery after central IL­1 
administration  likely  occurs  via  several  molecular  mecha­
nisms. Glucocorticoids directly transactivate the MuRF1 
gene in synergy with Foxo1 (Waddell et al., 2008). In addi­
tion, Foxo1 expression is induced by both central IL­1 and 
low­dose glucocorticoids. Although the principle mechanism 
for the regulation of the activity of Foxo transcription factors 
with regard to their catabolic activity is via Akt­dependent 
phosphorylation and nuclear exclusion (Sandri et al., 2004), 
we saw no evidence for alterations in the IGF­1–Akt signal­
ing pathway in response to central inflammation. However, 
increased levels of Foxo1 have been extensively correlated 
with atrophy (Jagoe et al., 2002; Lecker et al., 2004; Sacheck 
et al., 2007; Shimizu et al., 2011). Furthermore, overexpres­
sion of Foxo1 in muscle is sufficient to produce atrophy (Kamei 
et al., 2004). Myostatin is another mediator of skeletal muscle 
catabolism that is induced by central inflammation in an HPA 
axis–dependent manner. Blockade of myostatin signaling at­
tenuates the induction of MAFbx and MuRF1 in a variety of 
catabolic states (Zhou et al., 2010; Zhang et al., 2011). KLF15 
is another transcription factor that has recently been impli­
cated in the regulation of skeletal muscle catabolism. KLF15 
is directly induced by glucocorticoids and transactivates 
both MAFbx and MuRF1 (Shimizu et al., 2011). The sup­
pression of protein synthesis by glucocorticoids is also exe­
cuted via several distinct mechanisms, all converging to 
inhibit mTOR signaling. REDD1 is directly transactivated 
by the glucocorticoid receptor and inhibits mTOR activity 
via the tuberous sclerosis complex (Wang et al., 2006). Sestrin-1 
is another negative regulator of mTOR signaling in response 
to genotoxic stress via activation of the tuberous sclerosis 
complex and AMPK (Budanov and Karin, 2008). An integral 
role for sestrin signaling in the catabolic process has not yet 
been described; however, their role in metabolic signaling 
cascades makes them likely targets of future studies. Protein 
synthesis via the mTOR complex is also regulated by the 
transcription  factor  KLF15  (Shimizu  et  al.,  2011).  The 
concerted up­regulation of multiple inhibitors of mTOR 
signaling suggests that central inflammation elicits concerted 
decreases in protein synthesis and increases in protein break­
down to evoke atrophy.
We found a distinct set of genes that was regulated in skel­
etal muscle after IL­1 treatment and was not returned to 
Increased levels of circulating glucocorticoid are neces­
sary for muscle catabolism as a result of fasting (Wing and 
Goldberg, 1993), sepsis (Tiao et al., 1996), and acute diabetes 
(Hu et al., 2009), as adrenalectomy or administration of mife­
pristone attenuates muscle wasting in these states. Consistent 
with this, we found that central inflammation also requires an 
intact HPA axis to induce muscle catabolism. Furthermore, 
models of peripheral inflammation­induced muscle­wasting 
share a similar glucocorticoid­responsive gene expression sig­
nature, suggesting this response relies on HPA axis activation. 
Surprisingly, induction of the atrophy program by LPS was 
almost entirely blocked by adrenalectomy. LPS has been pro­
posed  to  induce  muscle  catabolism  via  direct  action  on 
muscle, or via the production of cytokine intermediates such 
as TNF or IL­1, which act directly on muscle (Li et al., 
2005, 2009; Doyle et al., 2011). Our data suggest that HPA 
axis activation is an integral part of the catabolic response to 
inflammation and that glucocorticoids may synergize with cyto­
kines acting directly on muscle to promote atrophy. Inter­
estingly,  muscle­specific  loss  of  function  of  the  cytokine 
receptor adaptor protein TRAF6 ameliorated tumor­induced 
muscle atrophy, implicating cytokine action on the myocyte 
as a mediator of atrophy (Paul et al., 2010). However, atrophy 
as a result of denervation is also attenuated in muscle­specific 
TRAF6 knockout mice. Given that denervation atrophy is 
not believed to occur via systemic inflammation, this finding 
suggests that TRAF6 may play some as yet unspecified role in 
muscle atrophy independent of its role in transducing inflam­
matory cytokine signals. Indeed, the inflammatory signaling 
apparatus has been generally implicated in mediating the atro­
phic response in skeletal muscle. NF­B activity is increased 
in the muscle of tumor­bearing mice, and dominant negative 
inhibition of NF­B signaling blocks tumor­associated muscle 
atrophy (Cai et al., 2004). NF­B also plays a critical role in 
the atrophy process in response to denervation and unloading, 
both of which are not thought to rely on systemic inflamma­
tion (Hunter and Kandarian, 2004; Mourkioti et al., 2006). 
Therefore, it is likely that signaling via TRAF6 and NF­B 
plays a fundamental role in atrophy beyond their role in the 
transduction of systemic inflammatory signals.
Despite  the  fact  that  elevated  glucocorticoid  levels  are 
found in models of cancer cachexia (Rivadeneira et al., 1999), 
it is widely accepted that they do not participate in muscle 
atrophy associated with tumor growth (Tessitore et al., 1994; 
Llovera et al., 1996). However, it is difficult to rule out a role 
for endogenous glucocorticoids on the basis of these studies. 
Two of these studies used the same tumor model (YAH­130), 
which grows in the peritoneal cavity and likely directly im­
pacts organ function. Furthermore, food intake was not re­
moved as a variable in these studies. Despite this, a trend 
toward improvement was observed in ADX tumor­bearing 
animals with regard to skeletal muscle protein content (Tessitore 
et al., 1994). Pharmacologic blockade of glucocorticoid re­
ceptors with mifepristone has been unsuccessful in cancer ca­
chexia; however, given the 1–2­h half­life of this drug in 
rodents (Heikinheimo et al., 1994), the once daily dosing was JEM Vol. 208, No. 12 
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by the indicated group. Rats were sacrificed by decapitation under isoflurane 
anesthesia, and mice were sacrificed by decapitation under anesthesia from a 
ketamine cocktail. Experiments were conducted in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals 
and approved by the Animal Care and Use Committee of Oregon Health & 
Science University.
Real-time PCR
Total  muscle  RNA  was  extracted  using  the  RNeasy  fibrous  tissue  mini   
kit (QIAGEN) and hypothalamic RNA was extracted using an RNeasy   
mini kit according to the manufacturer’s instructions. cDNA was tran­
scribed using TaqMan reverse transcription reagents and random hexamers 
according to the manufacturer’s instructions. PCR reactions were run on   
an ABI 7300 (Applied Biosystems), using TaqMan universal PCR master   
mix with the following TaqMan gene expression assays: mouse GAPDH 
(Mm99999915_g1),  mouse  MAFbx  (Mm00499518_m1),  mouse  MuRF1 
(Mm01185221_m1),  mouse  Foxo1  (Mm00490672_m1),  mouse  Lcn2 
(Mm01324470_m1),  mouse  Mt2  (Mm00809556_s1),  mouse  Sesn1 
(Mm01185732_m1), mouse DEPP (Mm04206895_m1), mouse UCP3 
(Mm00494077_m1), mouse FOXO3 (Mm01185722_m1), mouse Selp 
(Mm00441295_m1),  mouse  Nfkbia  (Mm00477798_m1),  mouse  Id3 
(Mm00492575_m1),  mouse  Ky  (Mm00600373_m1),  mouse  REDD1 
(Mm00512504_g1),  mouse  KLF15  (Mm00517792_m1),  rat  GAPDH 
(Rn99999916_s1), rat MAFbx (Rn00591730_m1), rat MuRF1 (Rn00590197_
m1),  rat  Foxo1  (Rn01494868_m1),  rat  IL­1  (Rn00580432_m1),  rat 
KLF15  (Rn00585508_m1),  rat  REDD1  (Rn01433735_g1),  rat  Sesn1 
(Rn01440906_m1), and rat Nfkbia (Rn01473657_g1; Applied Biosystems). 
Relative expression was calculated using the Ct method and was nor­
malized to Veh­treated control. Statistical analysis was performed on the 
normally distributed Ct values. For analyses involving two variables, raw 
data and two­way ANOVA results can be found in Table S1.
Microarray analysis
Gene expression microarrays were performed in the Department of Oncol­
ogy at the University of Alberta, Canada.
Synthesis of cRNA and cDNA, labeling, and hybridization of arrays. 
Protocols and temperature cycling conditions for cDNA synthesis and in vitro 
transcription of cRNA, hydrolysis of cRNA (by RNase H) and fragmentation 
(by APE 1), as well as labeling of single­stranded cDNA, were as described by 
the manufacturers (Ambion and Applied Biosystems) and the WT Expression 
kit (Ambion). The reaction mix contained 500 ng of total RNA. The reaction 
mix was spiked with Poly­A RNA (Product Number 900433) to monitor the 
amplification and labeling process independent of the quality of the initial total 
RNA used in the reactions. Reaction products at each of the synthesis steps 
were quantified using the NanoDrop 1000 spectrophotometer. Samples were 
biotinylated using the WT Terminal Labeling kit (Affymetrix) adhering to the 
experimental protocols described by the supplier. Samples were hybridized 
using the Gene Chip Hybridization Control kit (Affymetrix) and the 
GeneChip  Hybridization,  Wash,  and  Stain  kit  (Affymetrix).  Arrays  were 
scanned using the GeneChiP Scanner 3000 7G (Affymetrix).
Gene expression arrays. The total RNA was quantified using a Nano­
Drop 1000 Spectrophotometer (NanoDrop Technologies) and its integrity 
evaluated using a Bioanalyzer 2100 (Agilent Technologies) according to the 
manufacturer’s protocols. RNA samples with RNA integrity numbers >5.0 
were used in this study (mean of 28 samples is 6.68; maximum value at 8.3 
and minimum at 5.1). Mouse expression array (GeneChip Mouse Exon 1.0 ST 
Array; Affymetrix) were used to capture gene expression profiles in the sam­
ple sets. These arrays are designed to capture all exons, each with multiple 
probes per exon, and are amenable to analysis both for alternatively spliced 
transcripts (all exons individually) and gene­level expression from multiple 
probes from exons to yield a single expression level data point reflecting 
transcripts derived from a single gene. For the current analysis, we used 
gene­level expression analysis (core analysis) and deferred the exon/splice 
baseline by adrenalectomy. Although a causative role cannot be 
ascribed to any of these genes in central IL­1–induced muscle 
catabolism, this pattern does demonstrate a glucocorticoid­ 
independent effect of i.c.v. IL­1 on skeletal muscle. Recent 
work has shown that two discrete events are necessary for 
muscle catabolism in acute diabetes, where both a loss of skel­
etal muscle insulin signaling and pathophysiologic levels of 
glucocorticoid are required (Hu et al., 2009). Critical to the 
interpretation of these studies is the distinction between phys­
iological levels and pharmacologic dosing of glucocorticoids. 
It is well known that administration of the synthetic glucocor­
ticoid dexamethasone, in doses far exceeding the physiologi­
cal range, is sufficient to induce muscle atrophy (Bodine et al., 
2001a). However, when dexamethasone is given at a dose es­
timated to mimic endogenous activation of the HPA axis, no 
muscle atrophy is observed (Hu et al., 2009). In contrast, we 
demonstrated that administration of the endogenous gluco­
corticoid corticosterone, at a dose that mimics the inflamma­
tory activation of the HPA axis, produces dramatic muscle 
atrophy. This discrepancy is likely a result of the differences 
between  dexamethasone  and  corticosterone  including  po­
tency, metabolism, and activity at the mineralocorticoid re­
ceptor. Regardless, the levels of circulating corticosterone we 
achieved in this study are well within the physiological range 
and comparable with those seen in a multitude of diseases as­
sociated with muscle wasting (Tanaka et al., 1990; Llovera et al., 
1996). Therefore, it is likely that glucocorticoids are necessary 
and sufficient to explain a significant portion of muscle catab­
olism in many forms of chronic disease. However, the incom­
plete blockade of atrophy gene induction by ADX during 
both  central  and  systemic  inflammation  demonstrates  that 
other mechanisms play critical roles in regulating catabolism 
in response to inflammation.
The finding that CNS inflammation elicits muscle atro­
phy illustrates a new anatomical target for cytokine­induced 
muscle catabolism. This study is the first to demonstrate that 
inflammatory cytokines cause muscle breakdown by acting 
within the brain. In addition to the direct effects of inflam­
matory cytokines on skeletal muscle, the action of cytokines 
in the CNS to influence skeletal muscle metabolism must 
now be considered. The up­regulation of inflammatory cyto­
kines in the CNS in disease models of cachexia is well docu­
mented, indicating that this pathway is generally activated in 
diseases associated with muscle wasting. Further studies will 
likely examine the general contribution of the CNS­mediated 
muscle wasting in cachexia and may discover new therapeutic 
targets for muscle wasting diseases.
MATERIALS AND METHODS
Animals
20–25­g WT C57BL/6J mice were obtained from The Jackson Laboratory. 
250–350­g Sprague Dawley were purchased from Charles River. MC4RKO 
mice were as used as previously reported (Huszar et al., 1997). MC4RKO 
mice were backcrossed at least 10 generations into the C57BL/6J strain. All 
animals were maintained on a normal 12:12­h light/dark cycle and provided 
ad libitum access to water and food (rodent diet 5001; Purina Mills), except 
in the case of PF animals in which food intake was restricted to that consumed 2460 Inflammation induces atrophy via the CNS | Braun et al.
(model 2001; Alzet). Cannulas were implanted into the lateral ventricle under 
isoflurane anesthesia, using a stereotactic alignment instrument (Kopf) at the 
following coordinates relative to bregma: 1.5 mm X, 1.0 mm Y, and 
4.0 mm Z. Mini osmotic pumps delivering 10 ng rat IL­1 per hour 
(R&D Systems) were connected via polyethylene catheters to the cannulas 
and implanted subcutaneously. Body composition analysis was performed 
2 d before surgery, and again immediately before sacrifice, using an EchoMRI 
4­in­1 NMR system (EchoMRI).
Peripheral infusions
Mini osmotic pumps (model 1003D; Alzet) delivering 10 ng rat IL­1 per 
hour were implanted into the peritoneal cavity of Sprague Dawley rats under 
isoflurane  anesthesia.  Body  composition  analysis  was  performed  as  per 
chronic i.c.v. infusion.
LPS treatment
Mice were injected with 250 µg/kg LPS (Sigma­Aldrich) dissolved in nor­
mal saline/0.5% BSA and sacrificed 8 h later. For studies examining hypo­
thalamic gene expression, animals were perfused with DEPC­treated PBS 
before the dissection of hypothalamic blocks to remove circulating immune 
cells from the tissue.
Adrenalectomy
ADX animals were purchased from Charles River. Animals were implanted 
with  21­d  sustained  release  corticosterone  tablets  (Innovative  Research  of 
America) immediately after arrival.
Corticosterone pellet implantation
For corticosterone replacement in ADX animal, rats were implanted with 
35­mg tablets and mice were implanted subcutaneously with 1.5­mg tablets, 
both of which are known to produce low physiological levels of corticosterone 
(Kovács et al., 2000; Pruett and Padgett, 2004). Animals were maintained with 
0.9% saline drinking water and allowed to recover at least 1 wk before cannula 
implantation. To achieve stressed levels of circulating corticosterone, Sprague 
Dawley rats were implanted with 100­ or 2× 100­mg corticosterone tablets 
which are known to produce circulating levels approximating those seen in 
stressed animals (Kovács et al., 2000).
Western blotting
Muscles were homogenized in RIPA buffer (50 mM Tris, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X­100, 0.25% Na deoxycholate, and 1 mM 
NaF) and supplemented with Complete protease inhibitors and PhosSTOP 
phosphatase inhibitor (Roche) for 5 min using a Polytron homogenizer (Kine­
matica). Samples were incubated on ice for 1 h, and centrifuged at 13,000 RPM 
for 10 min at 4°C. 50 µg of total protein per lane was run on NuPage Bis­Tris 
4–12% gradient polyacrylamide gels (Invitrogen) and transferred to Immobilon­
FL PVDF membranes (Millipore). Proteins were detected using the following 
antibodies and quantitated using an Odyssey System (LI­COR Biosciences): 
rabbit anti–phospho AKT Ser473 D9E, mouse anti–Pan AKT 40D4, rabbit 
anti–phospho p38 Thr180/Tyr182 D3F9 (Cell Signaling Technology), E7 
tubulin (Developmental Studies Hybridoma Bank), IRDye 800CW goat anti–
mouse IgG, and IRDye 680LT goat anti–rabbit IgG (LI­COR Biosciences).
Plasma ELISA and RIA
IL­6 and IGF­1 were measured by ELISA (R&D Systems) according to the 
manufacturer’s instructions. Plasma corticosterone levels were measured by RIA 
(MP Biomedicals) according to the manufacturer’s instructions.
In situ hybridization
Rats were injected with 250 µg/kg LPS and sacrificed 8 h after injection. 20­µm 
coronal sections were cut on a cryostat and thaw­mounted onto Superfrost Plus 
slides (VWR Scientific). Hypothalamic sections were collected in a 1:6 series 
from the diagonal band of Broca (bregma, 0.50 mm) caudally through the mam­
millary bodies (bregma, 5.00 mm). 0.15 pmol/ml of an antisense 33P­labeled rat 
IL­1 riboprobe (corresponding to bases 316–762 of rat IL-1b; GenBank 
variant analysis for future data mining pending development of new analytical 
tools. The complete dataset has been deposited in the GEO Omnibus database 
(GEO Series accession no. GSE26766).
Data processing. The gene expression data were normalized and trans­
formed using GeneSpring GX 11.5. Using a Core analysis, the data were 
summarized using RMA16, log transformed, and baselined to the median in 
all samples. A one­way ANOVA was performed on the log2­normalized in­
tensities. After correcting the p­values for multiple comparisons using the 
Benjamini­Hochberg correction at a false discovery rate of 1%, 494 probes 
were declared significantly expressed (P < 2.8 × 105). Only probes that 
showed 1.75­fold up­ or down­regulation at any of the time points were 
considered. Genes were organized into functional categories based on 
GeneRIFs (National Center for Biotechnology Information) and reported 
function in skeletal muscle (Table S2).
Immunohistochemistry
Cryosections of Gn–soleus complex were cut in cross section. For laminin 
staining, 20­µm sections were fixed for 15 min in 4% PFA and then blocked 
in PBS (10 mM NaPO4 and150 mM NaCl)/10% BSA for 1 h at room tem­
perature. Sections were then incubated overnight at room temperature with 
a rabbit anti­laminin antibody (Sigma­Aldrich) diluted 1:50 in PBS/0.1% 
BSA, washed with PBS/0.025% Triton X­100, and incubated in a goat anti–
rabbit Alexa Fluor 488­ or 555­nm labeled secondary antibody (Invitrogen) 
diluted 1:500 in PBS/10% BSA. Sections were mounted with Vectashield 
fluorescent mounting media (Vector Laboratories). For analysis of muscle fiber 
type, 9 µm of unfixed cryosections were blocked for 1 h in PBS/1% BSA/10% 
goat serum and then incubated overnight in primary antibody diluted 1:250 
in PBS/1% BSA/10% goat serum. The following primary antibodies were 
used: SC­71 for myosin IIa, BF­F3 for myosin IIb (Developmental Studies 
Hybridoma Bank, University of Iowa, Iowa City, IA), and anti–Myosin I 
(Vector Laboratories). Sections were washed in PBS/0.025% Triton X­100 
and incubated with a goat anti–mouse Alexa Fluor 488 nm–labeled secondary 
antibody (Invitrogen) diluted 1:500 in PBS/10% BSA. Sections were mounted 
with Vectashield fluorescent mounting media. Fiber area was measured in 
images that were acquired on a (DM4000 B microscope; Leica), using a cam­
era (DFC340 FX; Leica) at ambient temperature at 100× magnification using 
Applications software (Suit 3.6; Leica). Images were segmented in ImageJ 
(National Institutes of Health) using a coherence enhanced diffusion filter. 
Images were pseudocolored using ImageJ. Images demonstrating fiber type 
distribution were obtained using a FW1000 confocal microscope at 100× using 
FluoView software (Olympus).
LLC tumor implantation
C57BL/6J mice were injected with (1 × 107 cells per site) Tumors were   
allowed to grow for 21 d and animals were sacrificed. Tumor weight at sacri­
fice averaged 2.4 ± 0.4 g. Gn muscle and hypothalamic blocks were stored 
in RNAlater (Ambion) according to the manufacturer’s instructions.
i.c.v. injection
For 26­gauge lateral ventricle cannulas (mice) and 22­gauge lateral ventricle 
cannulas (rats; PlasticsOne) under isoflurane anesthesia, a stereotactic align­
ment instrument (Kopf) was used at the following coordinates relative to 
bregma: for mice, 1.0 mm X, 0.5 mm Y, and 2.25 mm Z; for rats, 
1.5 mm X, 1.0 mm Y, and 4.0 mm Z. 10­ng mouse IL­1 (R&D 
Systems) injections were given in 1 µl total volume. IL­1 was dissolved in 
artificial cerebrospinal fluid (aCSF; 150 mM NaCl, 3 mM KCl, 1.4 mM 
CaCl2, 0.8 mM MgCl2, and 1.0 mM NaPO4) with 0.1% endotoxin free 
BSA. MTII (Phoenix Pharmaceuticals) was dissolved in aCSF and adminis­
tered at 1 nmol/5 µl volume. Chronic injections were performed by ad­
ministering MTII every 12 h for 36 h (four injections total). 10 mg/kg 
mifepristone (Sigma­Aldrich) was dissolved in sesame oil and administered 
30 min before i.c.v. injection and 4 h after i.c.v. injection.
Chronic lateral ventricle infusions were performed in Sprague Dawley 
rats using brain infusion kits (Brain Infusion kit II) and osmotic minipumps JEM Vol. 208, No. 12 
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accession no. NM_031512.2) was denatured, dissolved in hybridization buffer 
along with 1.7 mg/ ml tRNA, and applied to slides. Slides were covered with 
glass coverslips, placed in a humid chamber, and incubated overnight at 55°C. 
The following day, slides were treated with RNase A and washed under condi­
tions of increasing stringency. Slides were dipped in 100% ethanol, air dried, and 
then dipped in NTB­2 liquid emulsion (Kodak). Slides were developed 4 d later 
and cover slipped.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis was performed using 
Prism software (Version 4.0; Prism Software Corp.). All data were analyzed with 
either an unpaired Student’s t test, one­way ANOVA followed by a post hoc 
analysis using a Bonferroni’s corrected t test, or a two­way ANOVA followed 
with post hoc analysis using a Bonferroni’s corrected t test. For the measure­
ments of serum growth factors and hormones, some samples had undetectable 
levels of the analyte. For these analyses, normal distribution of the data cannot 
be assumed, and a Kruskal­Wallis test was used with a Dunn’s multiple compari­
son post test. For all analyses, significance was assigned at the level of P < 0.05.
Online supplemental material
Fig. S1 shows heat map data for the remainder of the microarray data meet­
ing the inclusion criteria not displayed in Fig. 5. Table S1 contains the raw 
dCT data from real­time PCR experiments in which two­way ANOVAs 
were performed and the corresponding p­values. Table S2 contains Gen­
Bank accession nos., where available, and p­values for all microarray probe 
sets meeting the inclusion criteria. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20111020/DC1.
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